Cat Feline Infectious Peritonitis: Welfare and Treatment

Feline infectious peritonitis was once invariably fatal, but antiviral treatments have transformed outcomes, making early diagnosis and access to treatment critical welfare priorities.

Key Facts

FIP is caused by a mutated form of feline coronavirus and was universally fatal until 2019.
The antiviral drug GS-441524 achieves remission in over 80% of treated cats.
FIP primarily affects young cats under three years, making it a particular concern for shelter populations.
Wet (effusive) FIP causes fluid accumulation and rapid deterioration without treatment.
Access to GS-441524 remains restricted in many countries due to licensing issues, forcing owners to access it illegally.

Welfare Considerations

The transformation of FIP from a death sentence to a treatable condition represents one of veterinary medicine's most significant recent advances. Cats diagnosed with FIP now have realistic prospects of full remission with antiviral treatment. However, the welfare impact of treatment barriers is severe — cats in countries without licensed access to GS-441524 face an agonising death that is now entirely preventable. Advocating for rapid regulatory approval of antiviral FIP treatments is a direct welfare intervention for thousands of cats annually.

What You Can Do

Seek veterinary assessment promptly if your cat shows fever, weight loss, or fluid accumulation.
Ask your vet about antiviral FIP treatment options including any available licensed products.
Support advocacy for rapid regulatory approval of GS-441524 and related antivirals in your country.
Connect with FIP support communities that can advise on treatment access in your jurisdiction.
Donate to FIP research organisations working to expand access to life-saving antiviral treatments.